ClinicalTrials.gg
CompletedNCT04681170Updated Aug 27, 2025Results posted

Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

A Phase 3 interventional study of Lomitapide in Homozygous Familial Hypercholesterolaemia (HoFH), sponsored by Amryt Pharma. Completed at 12 sites in 6 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Amryt Pharma (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
5 Years to 17 Years
Sex
All
01

Study summary

This is a single arm, open label, multi centre phase III study to evaluate the efficacy and long term safety of lomitapide in paediatric patients with HoFH receiving stable lipid lowering therapy (LLT) (including lipoprotein apheresis (LA), when applicable) comprising of the following phases:

  • Screening Period (starting at Week 12, i.e. ≤12 weeks prior to Baseline for up to 6 weeks)
  • Stratified Enrolment and Start of Run in Period (starting at minimum at Week 6, i.e., 6 weeks prior to Baseline for a minimum of 6 weeks):
  • Efficacy Phase (starting at Baseline, i.e. Day [D] 0 for 24 weeks±3 days
  • Safety Phase (starting at Week 24±3 days for 80±1 weeks)
Read the detailed description

Lomitapide has been approved for use in adult patients with HoFH in the European Union (EU) and European Economic Area (EEA), United States of America (USA), Israel, Argentina, Canada, Colombia, and Japan. This study is designed to determine if lomitapide is effective and can be safely administered to paediatric patients with HoFH. If the efficacy and safety so far observed in adults is confirmed in paediatric patients, the potential exists to significantly lower low-density lipoprotein cholesterol (LDL-C) levels in paediatric patients with HoFH. Furthermore, the lower LDL-C levels may reduce atherosclerosis progression and would be expected to benefit these paediatric patients with HoFH.

A single arm, non comparator design has been selected due to the rarity of the disease and because the evaluation of safety variables such as growth and sexual maturation requires longer term observation than would be feasible in the context of a placebo controlled study.

To mitigate the disadvantages of a single arm design, the study includes a Run in Period of at least 6 weeks during which current lipid lowering therapy (LLT) (including lipoprotein apheresis (LA), when applicable) will be stabilised to establish baseline levels allowing each patient to serve as his/her own control. Patients will also remain on stable LLT (including LA, when applicable) during the Efficacy Phase of the study through Week 24±3 days.

02

Conditions studied

  • Homozygous Familial Hypercholesterolaemia (HoFH)
03

In context

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

This study's enrollment of 46 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.

Browse Homozygous Familial Hypercholesterolemia studies →

Lead sponsor

Amryt Pharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted before Amryt Pharma became part of Chiesi Farmaceutici S.p.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 5 to ≤17 years with HoFH as defined by any of the following criteria recommended by the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) (Cuchel, Bruckert et al. 2014):

    1. Genetic confirmation of 2 mutant alleles at the LDL receptor (LDLR), apo B, Proprotein convertase subtilisin/kexin type 9 (PCSK9), or LDL receptor adapter protein 1 (LDLRAP1) gene locus OR
    2. An untreated LDL C >500 mg/dL (13 mmol/L) or treated LDL C ≥300 mg/dL (8 mmol/L ) together with either Cutaneous or tendon xanthoma before age 10 years or Untreated LDL C levels consistent with heterozygous FH in both parents
  • Baseline LDL C on LLT (maximum concentration [Cmax] immediately prior to LA, if applicable)

    1. >160 mg/dL (4.1 mmol/L, no documented cardiovascular disease [CVD]) or
    2. >130 mg/dL (3.4 mmol/L, established CVD defined as aortic valve disease and/or coronary atherosclerosis)
  • Body weight ≥15 kg or (BMI) and height both >10th percentile according to World Health Organization (WHO) Growth Charts for Boys and Girls 5 to 19 Years of Age
  • Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/ form, and has/have given written informed assent/consent
  • Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions, particularly that

    1. LLT (including LA, when applicable) must be stable for at least 6 weeks prior to Baseline (Run in Period) and remain stable through Week 24±3 days (end of Efficacy Phase)
    2. The patient must be compliant with both the low fat diet supplying \<20% of energy (calories) from fat or \<30 g fat, whichever is the lesser amount starting at the beginning of the Run in Period and the dietary supplement regimen starting at Week 2 of the Run in Period, both continuing until completion of the study
  • Postmenarchal female adolescents must be willing to use an effective form of with failure rates \<1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomy or vasectomised partner) during participation in the study (and at least 4 weeks thereafter). Patients taking oestrogen based oral contraceptives should be advised about possible loss of effectiveness due to diarrhea and/or vomiting. Additional contraceptive measures should be used for 7 days after resolution of symptoms.
  • Patient must be in stable physical and mental health at screening

Exclusion criteria

Exclusion criteria

  • Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism)
  • for the use of lomitapide according to section 4.3 of the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), such as to the active substance or to any of the listed in Section 6.1 of the SmPC, known significant or chronic inflammatory bowel disease or malabsorption
  • Moderate ( B) or severe hepatic impairment (Child Pugh C), active liver disease and/or abnormal liver function tests at screening ( or ALT >1.5 x (ULN) and/or total >1.5 x ULN in the absence of Gilbert's syndrome or AP >1.5 x ULN [based on appropriate age and gender normal values])
  • Serum CK >2 x ULN
  • Chronic renal insufficiency with (GFR) \<70 mL/min/1.73 m2 calculated using the Schwartz formula
  • Uncontrolled hypertension (defined as mean systolic and/or diastolic blood pressure ≥95% of normal for age and sex) despite medical therapy
  • (NYHA) Class III or IV congestive heart failure
  • Precocious/delayed puberty or endocrine disorder affecting growth (e.g., hypothyroidism, premature adrenarche)
  • History of drug abuse within the last 3 years or habitual alcohol consumption (defined as >1 ounce [28 g] of liquor or 4 ounce glass [113 g] of wine, or the equivalent, ≥3 times per week)
  • predicted to be \<5 years
  • History of a non skin (with the exception of cervical cancer in situ) within 3 years prior to enrolment
  • Treatment with any Medicinal Product (IMP) within 6 months or 5 times the terminal half life of the corresponding IMP, whichever is longer, before the screening visit
  • Patient is a dependent of the sponsor, of the investigational team or his/her immediate family
  • Pregnant or nursing women
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Other
    Age 5-10 years

    Lomitapide dosing commenced with 2mg at week 1 for 8 Weeks,then increased to 5mg at Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values.

    Drug: Lomitapide

  • Other
    Age 11-15 years

    Lomitapide dosing commenced with 2mg at week 1 for 4 Weeks, then increased to 5mg at Week 4±3 days, 10 mg at Week 8±3 days, 20mg at Week 12±3 days to the maximum allowable dose of 40mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values.

    Drug: Lomitapide

  • Other
    Age 16 to ≤17 years

    Lomitapide dosing commenced with 5mg at week 1 for 4 Weeks, then increased to 10mg at Week 4±3 days, 20 mg at Week 8±3 days, 40mg at Week 12±3 days to the maximum allowable dose of 60mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values.

    Drug: Lomitapide

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline

    To evaluate the efficacy of lomitapide, as defined by the percent change in low density lipoprotein cholesterol (LDL C) at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 24

Secondary outcomes

  1. Efficacy Endpoint: Percent Change From Baseline at Week 24 for Various Lipid Parameters

    To evaluate the efficacy of lomitapide, as defined by the percent change of the following lipid parameters at the maximum tolerated dose (MTD): * Non-high-density lipoprotein cholesterol (Non-HDL-C) * Total cholesterol (TC) * Very-low-density lipoprotein cholesterol (VLDL-C) * Apolipoprotein B (Apo B) * TG (Triglycerides)

    Time frame: Baseline through Week 24

  2. Efficacy Endpoint: Percent Change From Baseline at Week 24 for Lp(a)

    To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 24

  3. Percent Change From Baseline at All Other Time Points Through Week 104 for LDL-C

    To evaluate the efficacy of lomitapide, as defined by the percent change in LDL-C at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  4. Percent Change From Baseline at All Other Time Points Through Week 104 for Non-HDL-C

    To evaluate the efficacy of lomitapide, as defined by the percent change in Non-HDL-C at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  5. Percent Change From Baseline at All Other Time Points Through Week 104 for TC

    To evaluate the efficacy of lomitapide, as defined by the percent change in TC at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  6. Percent Change From Baseline at All Other Time Points Through Week 104 for VLDL-C

    To evaluate the efficacy of lomitapide, as defined by the percent change in VLDL-C at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  7. Percent Change From Baseline at All Other Time Points Through Week 104 for Apo B

    To evaluate the efficacy of lomitapide, as defined by the percent change in apo B at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  8. Percent Change From Baseline at All Other Time Points Through Week 104 for TG

    To evaluate the efficacy of lomitapide, as defined by the percent change in TG at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  9. Percent Change From Baseline at All Other Time Points Through Week 104 for Lipoprotein(a) (Lp(a))

    To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  10. Percent Change in TC/HDL-C Ratio From Baseline at All Other Time Points to Week 104

    To evaluate the efficacy of lomitapide, as defined by the percent change in TC/HDL-C ratio at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104

  11. Percent Change in HDL-C From Baseline at All Other Time Points to Week 104

    To evaluate the efficacy of lomitapide, as defined by the percent change in HDL-C at the maximum tolerated dose (MTD)

    Time frame: Baseline through Week 104 week

  12. Change in LLT From Week 28 Through Week 104

    To evaluate the efficacy of lomitapide, as defined by the change in background lipid lowering therapy

    Time frame: Week 28 through Week 104

  13. Change in LA From Week 28 Through Week 104

    To evaluate the efficacy of lomitapide, as defined by the change in lipoprotein apheresis

    Time frame: Week 28 through Week 104

  14. Number and Percentage of Patients Achieving European Atherosclerosis Society (EAS) Recommended Target (2013) of LDL-C at Any Timepoint Between Baseline and Week 24

    To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C

    Time frame: Baseline through Week 24

  15. Number and Percentage of Patients Achieving EAS Recommended Target (2013) of LDL-C at Any Time in the Study

    To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C

    Time frame: Baseline through Week 104

Other outcomes

  1. Percent Change of Body Mass Index (BMI)

    To evaluate the efficacy of lomitapide, as defined by the percent change of BMI

    Time frame: Baseline through Week 104

  2. Lipid Accumulation in the Liver Over Time Measured by Nuclear Magnetic Resonance (NMR) at Baseline and at Week 24, Week 56 and at Week 104

    To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by nuclear magnetic resonance (NMR)

    Time frame: Baseline through Week 104

  3. Lipid Accumulation in the Liver Over Time Measured by Ultrasound at Baseline and at Week 24, Week 56 and at Week 104

    To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by ultrasound

    Time frame: Baseline through Week 104

07

Results

Posted Aug 27, 2025
Limitations and caveats
Lp(a) analysis was analysed locally as central analysis was only available from January 2022.

Participant flow

Male and female subjects aged 5 to ≤17 years with HoFH were enrolled in the trial at 12 study centres in various countries (3 in Germany, 1 in Israel, 2 in Italy, 2 in Saudi Arabia, 3 in Spain and 1 in Tunisia). The first patient first visit was 14 Dec 2020 and the last patient last visit was 06 Jun 2024.

Pre-run in
Participant flow — Pre-run in
MilestoneAge 5-10 YearsAge 11-17 Years
Started2125
Completed2125
Not completed00
Stratified Enrolment & run-in
Participant flow — Stratified Enrolment & run-in
MilestoneAge 5-10 YearsAge 11-17 Years
Started2125
Completed2023
Not completed12
Withdrew: Death10
Withdrew: Withdrawal by subject01
Withdrew: Protocol violation01
Open Label Efficacy Phase
Participant flow — Open Label Efficacy Phase
MilestoneAge 5-10 YearsAge 11-17 Years
Started2023
Completed2021
Not completed02
Withdrew: Adverse event02
Open Label Safety Phase
Participant flow — Open Label Safety Phase
MilestoneAge 5-10 YearsAge 11-17 Years
Started2021
Completed2019
Not completed02
Withdrew: Withdrawal by subject01
Withdrew: Aes and none compliance01

Outcome measures

PrimaryEfficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline

To evaluate the efficacy of lomitapide, as defined by the percent change in low density lipoprotein cholesterol (LDL C) at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 24
Reported as:
Mean · Percent change from Baseline
Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline-53.910 ± 25.8287-56.529 ± 26.5401-51.633 ± 25.5658
Statistical analysis
  • All Age Groups · t-test, 1 sided · p = <0.0001 · Mean difference (net): -53.910 · 95% CI -61.8590 to -45.9612
SecondaryEfficacy Endpoint: Percent Change From Baseline at Week 24 for Various Lipid Parameters

To evaluate the efficacy of lomitapide, as defined by the percent change of the following lipid parameters at the maximum tolerated dose (MTD): * Non-high-density lipoprotein cholesterol (Non-HDL-C) * Total cholesterol (TC) * Very-low-density lipoprotein cholesterol (VLDL-C) * Apolipoprotein B (Apo B) * TG (Triglycerides)

Time frame:
Baseline through Week 24
Reported as:
Mean · Percent change from Baseline
Efficacy Endpoint: Percent Change From Baseline at Week 24 for Various Lipid Parameters
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Non-HDL-C-54.185 ± 25.0256-56.655 ± 25.9804-52.038 ± 24.5423
TC-50.176 ± 24.5397-52.883 ± 25.6260-47.822 ± 23.8756
VLDL-C-49.678 ± 31.6126-53.030 ± 28.0698-46.763 ± 34.7606
Apo B-53.1 ± 24.76-56.2 ± 24.45-50.4 ± 25.26
TG-49.28 ± 31.7290-52.292 ± 27.8956-46.674 ± 35.1359
SecondaryEfficacy Endpoint: Percent Change From Baseline at Week 24 for Lp(a)

To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 24
Reported as:
Mean · Percent change from Baseline
Efficacy Endpoint: Percent Change From Baseline at Week 24 for Lp(a)
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Efficacy Endpoint: Percent Change From Baseline at Week 24 for Lp(a)-26.757 ± 32.5675-17.248 ± 36.4246-36.996 ± 25.3314
SecondaryPercent Change From Baseline at All Other Time Points Through Week 104 for LDL-C

To evaluate the efficacy of lomitapide, as defined by the percent change in LDL-C at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change From Baseline at All Other Time Points Through Week 104 for LDL-C
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 4-1.962 ± 20.7168-5.936 ± 10.84381.651 ± 26.5109
Week 8-6.798 ± 19.1524-2.037 ± 11.8697-11.058 ± 23.3978
Week 12-16.638 ± 23.1978-11.742 ± 16.1686-21.289 ± 27.9618
Week 16-36.458 ± 17.9894-32.971 ± 14.6467-40.163 ± 20.8120
Week 20-50.730 ± 24.8321-49.906 ± 25.1366-51.476 ± 25.1505
Week 24-54.602 ± 26.4557-55.825 ± 27.9112-53.554 ± 25.7903
Week 28-55.518 ± 28.5714-57.929 ± 29.0704-53.108 ± 28.6469
Week 32-52.126 ± 28.7496-55.561 ± 29.7938-48.086 ± 27.8122
Week 36-39.823 ± 32.6612-45.072 ± 32.4809-34.574 ± 32.9076
Week 40-49.427 ± 29.5830-52.511 ± 27.4375-46.637 ± 31.8088
Week 44-44.312 ± 30.3775-53.502 ± 25.8673-35.122 ± 32.3611
Week 48-45.315 ± 29.6526-53.965 ± 23.2741-37.963 ± 32.9544
Week 52-44.583 ± 32.8128-52.956 ± 25.8671-35.718 ± 37.6118
Week 56-45.994 ± 34.3631-57.616 ± 28.1958-33.761 ± 36.6832
Week 68-40.831 ± 37.3821-52.220 ± 24.9512-31.151 ± 43.6898
Week 80-42.319 ± 34.9400-49.410 ± 28.8677-35.227 ± 39.6221
Week 92-37.199 ± 39.6625-41.059 ± 33.6178-32.910 ± 46.0836
Week 104-40.159 ± 30.5026-43.168 ± 25.4634-37.150 ± 35.3743
SecondaryPercent Change From Baseline at All Other Time Points Through Week 104 for Non-HDL-C

To evaluate the efficacy of lomitapide, as defined by the percent change in Non-HDL-C at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change From Baseline at All Other Time Points Through Week 104 for Non-HDL-C
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 4-1.765 ± 21.1682-5.950 ± 10.58812.039 ± 27.2319
Week 8-6.745 ± 18.6776-1.938 ± 12.1118-11.045 ± 22.5075
Week 12-16.497 ± 22.9850-12.039 ± 15.5376-20.733 ± 28.0917
Week 16-36.610 ± 17.4339-33.214 ± 14.6890-40.218 ± 19.7812
Week 20-50.928 ± 24.3958-50.150 ± 24.7267-51.632 ± 24.6817
Week 24-55.033 ± 25.4297-56.006 ± 27.3439-54.200 ± 24.3220
Week 28-55.984 ± 27.5559-58.201 ± 28.4121-53.768 ± 27.2620
Week 32-52.629 ± 27.8748-55.742 ± 29.1688-49.171 ± 26.7611
Week 36-40.574 ± 31.4293-45.464 ± 31.6491-35.685 ± 31.3277
Week 40-50.013 ± 28.4878-52.837 ± 26.6409-47.458 ± 30.4850
Week 44-44.702 ± 29.8885-53.685 ± 25.3674-35.720 ± 31.9421
Week 48-46.770 ± 29.3974-55.873 ± 23.6964-38.577 ± 32.1148
Week 52-45.222 ± 31.9577-53.190 ± 25.4004-36.785 ± 36.5745
Week 56-46.558 ± 33.4734-57.724 ± 27.7033-34.805 ± 35.6510
Week 68-41.576 ± 36.0854-52.331 ± 24.4942-32.433 ± 42.0777
Week 80-42.388 ± 34.3439-49.605 ± 28.2105-35.171 ± 38.9712
Week 92-37.755 ± 38.4243-41.420 ± 32.7680-33.682 ± 44.4970
Week 104-40.511 ± 30.1102-43.555 ± 24.5843-37.468 ± 35.2966
SecondaryPercent Change From Baseline at All Other Time Points Through Week 104 for TC

To evaluate the efficacy of lomitapide, as defined by the percent change in TC at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change From Baseline at All Other Time Points Through Week 104 for TC
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 4-2.057 ± 19.3772-5.487 ± 10.23521.062 ± 24.8373
Week 8-6.970 ± 17.6904-3.092 ± 13.2354-10.643 ± 20.7648
Week 12-15.961 ± 21.4313-12.881 ± 15.4304-19.041 ± 26.1667
Week 16-33.976 ± 15.7159-30.986 ± 14.0719-37.154 ± 17.1693
Week 20-48.177 ± 23.2987-48.524 ± 23.7013-47.847 ± 23.4897
Week 24-50.922 ± 24.9738-52.132 ± 26.9234-49.885 ± 23.7998
Week 28-51.998 ± 26.9668-54.806 ± 27.4139-49.190 ± 26.9564
Week 32-48.945 ± 26.2375-52.642 ± 27.5342-44.838 ± 24.8402
Week 36-40.643 ± 30.5125-45.656 ± 29.7175-35.365 ± 31.2402
Week 40-45.402 ± 27.5358-46.997 ± 27.2264-43.882 ± 28.4123
Week 44-41.443 ± 28.3745-50.186 ± 24.6881-32.699 ± 29.7008
Week 48-44.164 ± 27.6987-53.422 ± 22.4426-35.369 ± 29.8353
Week 52-42.764 ± 30.6617-51.169 ± 24.8422-33.371 ± 34.4186
Week 56-43.234 ± 31.3599-54.109 ± 26.0580-31.787 ± 33.0105
Week 68-39.672 ± 33.2025-49.108 ± 24.7124-30.236 ± 38.2710
Week 80-40.291 ± 31.9119-48.031 ± 26.5964-32.143 ± 35.5890
Week 92-34.946 ± 35.8485-38.474 ± 31.6123-31.025 ± 40.6102
Week 104-36.017 ± 32.2354-42.430 ± 24.0856-29.605 ± 38.3282
SecondaryPercent Change From Baseline at All Other Time Points Through Week 104 for VLDL-C

To evaluate the efficacy of lomitapide, as defined by the percent change in VLDL-C at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change From Baseline at All Other Time Points Through Week 104 for VLDL-C
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 49.770 ± 42.20291.911 ± 30.662416.914 ± 50.1439
Week 82.857 ± 34.58875.190 ± 35.03310.771 ± 35.0086
Week 12-7.405 ± 48.8428-6.638 ± 54.7493-8.133 ± 43.9360
Week 16-34.706 ± 31.6590-36.773 ± 23.3455-32.509 ± 39.3305
Week 20-49.068 ± 25.6958-51.943 ± 26.4251-46.467 ± 25.3796
Week 24-53.050 ± 27.2118-54.447 ± 27.8824-51.853 ± 27.2551
Week 28-55.394 ± 25.0601-58.209 ± 24.3762-52.579 ± 26.0764
Week 32-47.899 ± 55.7396-54.787 ± 28.1792-39.796 ± 76.9320
Week 36-46.596 ± 25.9994-47.963 ± 24.7584-45.230 ± 27.8348
Week 40-51.167 ± 26.7498-55.266 ± 21.3853-47.458 ± 30.8760
Week 44-46.750 ± 33.3163-54.803 ± 19.0837-38.696 ± 42.1620
Week 48-38.148 ± 50.6100-50.109 ± 35.8714-27.981 ± 59.4366
Week 52-49.469 ± 30.0996-55.576 ± 20.3440-43.004 ± 37.4046
Week 56-47.051 ± 32.7429-55.292 ± 28.1394-38.375 ± 35.6732
Week 68-47.832 ± 30.6844-50.902 ± 21.1040-45.223 ± 37.3270
Week 80-36.881 ± 44.5589-46.520 ± 29.3256-27.242 ± 55.0014
Week 92-41.368 ± 31.7375-44.652 ± 23.2247-37.718 ± 39.5304
Week 104-39.055 ± 40.2422-44.612 ± 26.8209-33.498 ± 50.5480
SecondaryPercent Change From Baseline at All Other Time Points Through Week 104 for Apo B

To evaluate the efficacy of lomitapide, as defined by the percent change in apo B at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change From Baseline at All Other Time Points Through Week 104 for Apo B
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 40.2 ± 18.99-0.5 ± 16.450.9 ± 21.41
Week 8-6.5 ± 19.25-2.4 ± 16.63-10.3 ± 21.15
Week 12-15.5 ± 21.91-10.3 ± 14.37-20.8 ± 26.84
Week 16-36.1 ± 16.70-32.6 ± 14.52-39.7 ± 18.50
Week 20-51.6 ± 24.21-52.1 ± 24.26-51.2 ± 24.76
Week 24-54.0 ± 25.02-55.4 ± 25.73-52.7 ± 24.96
Week 28-56.2 ± 26.17-59.2 ± 25.77-53.2 ± 26.91
Week 32-52.0 ± 28.64-55.7 ± 27.78-47.8 ± 29.80
Week 36-43.9 ± 30.91-47.4 ± 31.45-40.3 ± 30.74
Week 40-48.9 ± 29.11-50.6 ± 27.92-47.3 ± 30.81
Week 44-46.1 ± 28.75-53.5 ± 25.61-38.7 ± 30.42
Week 48-48.6 ± 29.03-56.9 ± 24.99-40.7 ± 30.97
Week 52-47.7 ± 30.16-55.4 ± 26.77-39.1 ± 32.14
Week 56-47.1 ± 33.06-57.7 ± 28.41-35.9 ± 34.63
Week 68-44.8 ± 33.99-53.9 ± 24.92-35.7 ± 39.71
Week 80-47.1 ± 30.58-53.7 ± 25.96-40.0 ± 34.09
Week 92-41.8 ± 35.12-45.5 ± 28.97-37.7 ± 41.39
Week 104-44.6 ± 30.22-51.1 ± 22.42-38.1 ± 35.85
SecondaryPercent Change From Baseline at All Other Time Points Through Week 104 for TG

To evaluate the efficacy of lomitapide, as defined by the percent change in TG at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change From Baseline at All Other Time Points Through Week 104 for TG
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 49.387 ± 41.72331.699 ± 32.134216.376 ± 48.5494
Week 82.649 ± 35.31155.577 ± 36.30360.029 ± 35.1807
Week 12-7.258 ± 49.6990-6.133 ± 56.7548-8.327 ± 43.4273
Week 16-34.970 ± 30.2259-37.161 ± 23.9242-32.643 ± 36.4318
Week 20-48.989 ± 25.8872-51.346 ± 27.1808-46.856 ± 25.1360
Week 24-52.878 ± 26.8475-53.866 ± 27.5741-52.031 ± 26.8624
Week 28-55.639 ± 24.6317-57.852 ± 24.1398-53.426 ± 25.5749
Week 32-48.697 ± 54.0396-54.381 ± 28.4810-42.380 ± 73.2737
Week 36-46.823 ± 25.4762-48.286 ± 23.9243-45.361 ± 27.5563
Week 40-51.612 ± 25.9533-55.105 ± 20.8662-48.451 ± 29.9921
Week 44-47.065 ± 31.7596-54.885 ± 18.5911-39.245 ± 39.9507
Week 48-39.769 ± 48.3307-51.803 ± 35.2601-28.939 ± 56.3536
Week 52-49.415 ± 28.4096-55.142 ± 20.0234-43.352 ± 34.8302
Week 56-47.707 ± 32.0150-55.648 ± 26.7620-39.349 ± 35.5528
Week 68-48.471 ± 30.8061-51.253 ± 21.5583-46.107 ± 37.3356
Week 80-38.312 ± 44.1074-47.765 ± 27.6927-28.860 ± 55.1679
Week 92-41.549 ± 30.2027-45.140 ± 23.5731-37.558 ± 36.5005
Week 104-39.739 ± 39.8597-45.352 ± 25.8574-34.126 ± 50.4118
SecondaryPercent Change From Baseline at All Other Time Points Through Week 104 for Lipoprotein(a) (Lp(a))

To evaluate the efficacy of lomitapide, as defined by the percent change in Lp(a) at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change From Baseline at All Other Time Points Through Week 104 for Lipoprotein(a) (Lp(a))
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 49.660 ± 63.576824.269 ± 84.1451-6.072 ± 23.8773
Week 81.508 ± 46.115613.870 ± 54.0530-13.327 ± 30.7067
Week 120.592 ± 32.524113.509 ± 36.2732-15.847 ± 17.2462
Week 16-14.648 ± 26.3140-6.564 ± 29.3156-26.775 ± 15.7748
Week 20-16.602 ± 47.9856-3.961 ± 58.6273-31.540 ± 26.7998
Week 24-28.874 ± 33.5277-15.021 ± 38.1874-42.728 ± 21.9120
Week 28-32.628 ± 32.4047-23.314 ± 36.5744-46.081 ± 20.1331
Week 32-20.594 ± 50.1160-27.534 ± 46.6328-10.877 ± 55.6561
Week 36-25.278 ± 32.4201-21.547 ± 36.2351-32.741 ± 23.6913
Week 40-28.257 ± 34.6849-20.400 ± 39.7347-40.480 ± 21.6021
Week 44-30.124 ± 34.9943-25.915 ± 38.3512-37.940 ± 28.7510
Week 48-17.905 ± 38.3429-8.621 ± 43.0927-35.145 ± 20.2017
Week 52-25.635 ± 42.3832-17.270 ± 47.3261-41.170 ± 27.8522
Week 56-22.366 ± 34.5809-14.691 ± 33.9040-36.621 ± 33.5132
Week 68-20.634 ± 42.9257-9.136 ± 47.0506-41.989 ± 24.2691
Week 80-22.659 ± 42.2271-19.135 ± 48.3708-30.295 ± 26.4884
Week 92-22.235 ± 41.1508-16.468 ± 44.0841-37.229 ± 31.2661
Week 104-29.064 ± 34.5930-24.776 ± 37.6534-40.212 ± 24.8480
SecondaryPercent Change in TC/HDL-C Ratio From Baseline at All Other Time Points to Week 104

To evaluate the efficacy of lomitapide, as defined by the percent change in TC/HDL-C ratio at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change in TC/HDL-C Ratio From Baseline at All Other Time Points to Week 104
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 40.108 ± 27.5756-10.581 ± 14.94899.825 ± 32.7827
Week 8-5.292 ± 29.1737-7.941 ± 22.3051-2.921 ± 34.6428
Week 12-14.501 ± 27.7248-13.695 ± 24.7560-15.266 ± 30.9105
Week 16-33.384 ± 25.8765-38.768 ± 21.4831-27.664 ± 29.4691
Week 20-45.689 ± 27.0372-51.512 ± 24.7014-40.421 ± 28.5476
Week 24-52.155 ± 25.1906-60.174 ± 23.4381-45.281 ± 25.1244
Week 28-50.986 ± 31.0715-59.358 ± 27.4688-42.614 ± 32.8937
Week 32-48.651 ± 35.4572-55.596 ± 32.8921-40.934 ± 37.5141
Week 36-35.860 ± 35.4801-45.043 ± 34.3337-26.677 ± 35.1331
Week 40-43.976 ± 36.8573-56.120 ± 26.2125-32.988 ± 41.9967
Week 44-40.395 ± 38.1876-54.594 ± 28.2165-26.197 ± 42.1040
Week 48-41.720 ± 36.2674-54.921 ± 27.6549-29.839 ± 39.5405
Week 52-43.496 ± 38.2302-57.568 ± 26.0987-28.596 ± 43.8568
Week 56-39.188 ± 55.5616-57.116 ± 31.2556-20.317 ± 68.9419
Week 68-36.874 ± 41.9020-54.241 ± 26.5277-22.111 ± 47.2744
Week 80-39.189 ± 37.9268-49.165 ± 33.2083-29.213 ± 40.5453
Week 92-37.274 ± 41.0451-47.527 ± 33.5384-25.882 ± 46.3515
Week 104-39.358 ± 34.3438-48.484 ± 25.6330-30.233 ± 39.9837
SecondaryPercent Change in HDL-C From Baseline at All Other Time Points to Week 104

To evaluate the efficacy of lomitapide, as defined by the percent change in HDL-C at the maximum tolerated dose (MTD)

Time frame:
Baseline through Week 104 week
Reported as:
Mean · Percent change from Baseline
Percent Change in HDL-C From Baseline at All Other Time Points to Week 104
Percent change from BaselineAll Age GroupsAge 5-10 YearsAge 11-17 Years
Week 41.428 ± 19.62807.659 ± 16.3760-4.236 ± 20.9511
Week 84.482 ± 26.063512.855 ± 29.0476-3.010 ± 21.1047
Week 124.912 ± 29.12158.692 ± 27.60731.322 ± 30.7607
Week 168.059 ± 31.460419.392 ± 24.6238-3.984 ± 34.1243
Week 206.186 ± 33.366417.873 ± 30.1872-4.387 ± 33.2219
Week 2411.412 ± 33.004424.967 ± 28.3089-0.208 ± 32.8835
Week 2811.154 ± 36.313319.883 ± 27.98092.425 ± 42.0330
Week 3215.137 ± 33.930419.607 ± 31.209210.171 ± 36.9795
Week 368.537 ± 30.221814.424 ± 29.71102.651 ± 30.4028
Week 4010.043 ± 35.009725.145 ± 32.0096-3.620 ± 32.4844
Week 4412.765 ± 33.213622.486 ± 34.69333.044 ± 29.3561
Week 4813.602 ± 37.573225.097 ± 42.36923.256 ± 30.0858
Week 5218.032 ± 35.107931.674 ± 35.78523.587 ± 28.7665
Week 5611.528 ± 29.175021.636 ± 31.09750.887 ± 23.3045
Week 689.557 ± 30.661621.183 ± 29.0036-0.326 ± 29.1404
Week 8011.606 ± 30.824217.203 ± 31.17886.010 ± 30.2457
Week 9217.320 ± 33.002429.691 ± 32.67333.574 ± 28.2358
Week 10416.109 ± 37.298726.224 ± 38.97805.994 ± 33.6550
SecondaryChange in LLT From Week 28 Through Week 104

To evaluate the efficacy of lomitapide, as defined by the change in background lipid lowering therapy

Time frame:
Week 28 through Week 104
Reported as:
Count of participants · Participants
Change in LLT From Week 28 Through Week 104
ParticipantsAll Age GroupsAge 5-10 YearsAge 11-17 Years
Reduction due to low LDL-C211
Discontinuation due to lomitapide increase110
Discontinuation due to other reason211
Increase due to high LDL-C330
Increase due to other reason110
SecondaryChange in LA From Week 28 Through Week 104

To evaluate the efficacy of lomitapide, as defined by the change in lipoprotein apheresis

Time frame:
Week 28 through Week 104
Reported as:
Count of participants · Participants
Change in LA From Week 28 Through Week 104
ParticipantsAll Age GroupsAge 5-10 YearsAge 11-17 Years
Reduction due to Adverse Event (AE)110
Reduction due to low LDL-C312
Reduction due to other reason431
Discontinuation due to low LDL-C110
Discontinuation due to other reason110
SecondaryNumber and Percentage of Patients Achieving European Atherosclerosis Society (EAS) Recommended Target (2013) of LDL-C at Any Timepoint Between Baseline and Week 24

To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C

Time frame:
Baseline through Week 24
Reported as:
Count of participants · Participants
Number and Percentage of Patients Achieving European Atherosclerosis Society (EAS) Recommended Target (2013) of LDL-C at Any Timepoint Between Baseline and Week 24
ParticipantsAll Age GroupsAge 5-10 YearsAge 11-17 Years
<135 mg/dL - anytime up to Week 2418711
<115 mg/dL - anytime up to Week 2416511
<110 mg/dL - anytime up to Week 2414410
SecondaryNumber and Percentage of Patients Achieving EAS Recommended Target (2013) of LDL-C at Any Time in the Study

To evaluate the efficacy of lomitapide, as defined by the number and percentage of patients achieving EAS recommended target (2013) of LDL-C

Time frame:
Baseline through Week 104
Reported as:
Count of participants · Participants
Number and Percentage of Patients Achieving EAS Recommended Target (2013) of LDL-C at Any Time in the Study
ParticipantsAll Age GroupsAge 5-10 YearsAge 11-17 Years
<135 mg/dL - anytime up to week 104231013
<115 mg/dL - anytime up to week 10420713
<110 mg/dL - anytime up to week 10419613
Other pre-specifiedPercent Change of Body Mass Index (BMI)

To evaluate the efficacy of lomitapide, as defined by the percent change of BMI

Time frame:
Baseline through Week 104
Reported as:
Mean · Percent change from Baseline
Percent Change of Body Mass Index (BMI)
Percent change from BaselineAll Age Groups
Week 4-1.06 ± 3.466
Week 8-1.32 ± 3.954
Week 12-2.36 ± 4.768
Week 16-2.96 ± 5.288
Week 20-4.21 ± 5.708
Week 24-5.04 ± 5.997
Week 28-4.13 ± 6.427
Week 32-3.60 ± 7.145
Week 36-3.92 ± 7.949
Week 40-3.78 ± 8.293
Week 44-3.71 ± 10.406
Week 48-3.92 ± 10.420
Week 52-3.21 ± 10.738
Week 56-2.90 ± 11.520
Week 68-3.00 ± 12.103
Week 80-1.90 ± 12.665
Week 92-1.00 ± 14.108
Week 104-0.11 ± 13.718
Other pre-specifiedLipid Accumulation in the Liver Over Time Measured by Nuclear Magnetic Resonance (NMR) at Baseline and at Week 24, Week 56 and at Week 104

To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by nuclear magnetic resonance (NMR)

Time frame:
Baseline through Week 104
Reported as:
Count of participants · Participants
Lipid Accumulation in the Liver Over Time Measured by Nuclear Magnetic Resonance (NMR) at Baseline and at Week 24, Week 56 and at Week 104
Participants5-10 Years11-17 Years
Baseline - ≤10% liver fat216
Baseline - >10% and ≤20% liver fat01
Baseline - >20% liver fat00
Week 24 - ≤10% liver fat112
Week 24 - >10% and ≤20% liver fat12
Week 24 - >20% liver fat01
Week 24 - No result24
Week 56 - ≤10% liver fat09
Week 56 - >10% and ≤20% liver fat14
Week 56 - >20% liver fat00
Week 56 - No result25
Week 104/EoT - ≤10% liver fat311
Week 104/EoT - >10% and ≤20% liver fat14
Week 104/EoT - >20% liver fat00
Other pre-specifiedLipid Accumulation in the Liver Over Time Measured by Ultrasound at Baseline and at Week 24, Week 56 and at Week 104

To evaluate the safety of lomitapide, as defined by lipid accumulation in the liver as measured by ultrasound

Time frame:
Baseline through Week 104
Reported as:
Count of participants · Participants
Lipid Accumulation in the Liver Over Time Measured by Ultrasound at Baseline and at Week 24, Week 56 and at Week 104
Participants5-10 Years11-17 Years
Baseline - ≤10% liver fat172
Baseline - >10% and ≤20% liver fat00
Baseline - >20% liver fat00
Week 24 - ≤10% liver fat152
Week 24 - >10% and ≤20% liver fat00
Week 24 - >20% liver fat00
Week 24 - No result00
Week 56 - ≤10% liver fat152
Week 56 - >10% and ≤20% liver fat10
Week 56 - >20% liver fat00
Week 56 - No result00
Week 104/EoT - ≤10% liver fat150
Week 104/EoT - >10% and ≤20% liver fat01
Week 104/EoT - >20% liver fat00

Adverse events

Collected over AEs were monitored throughout the study from the time of informed consent through Week 108.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Age 5-10 Years1/20 (5%)4/20 (20%)19/20 (95%)
Age 11-17 Years1/23 (4.3%)7/23 (30.4%)23/23 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventAge 5-10 YearsAge 11-17 Years
Vascular device occlusionGeneral disorders2/200/23
Vascular device infectionInfections and infestations0/202/23
Transaminases increasedInvestigations1/200/23
CataractEye disorders1/200/23
AppendicitisInfections and infestations1/200/23
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications0/201/23
Shunt occlusionInjury, poisoning and procedural complications0/201/23
Subdural haematomaInjury, poisoning and procedural complications0/201/23
Aortic arteriosclerosisVascular disorders0/201/23
Aortic valve disease mixedCardiac disorders0/201/23
Most frequent other events
Showing 10 of 74
Most frequent other events
EventAge 5-10 YearsAge 11-17 Years
DiarrhoeaGastrointestinal disorders9/2013/23
PyrexiaGeneral disorders10/204/23
VomitingGastrointestinal disorders10/202/23
Abdominal painGastrointestinal disorders8/2011/23
Alanine aminotransferase increasedInvestigations9/208/23
Aspartate aminotransferase increasedInvestigations7/208/23
CoughRespiratory, thoracic and mediastinal disorders6/201/23
AnaemiaBlood and lymphatic system disorders3/205/23
COVID-19Infections and infestations4/205/23
Blood creatine phosphokinase increasedInvestigations4/202/23

Baseline characteristics

Baseline data shown are for participants who completed the baseline visit.

Age, Categorical
Age, Categorical(Participants)Age 5-10 YearsAge 11-17 YearsTotal
<=18 years202343
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Age 5-10 YearsAge 11-17 YearsTotal
Mean7.0 ± 1.5414.0 ± 1.9710.7 ± 3.99
Sex: Female, Male
Sex: Female, Male(Participants)Age 5-10 YearsAge 11-17 YearsTotal
Female101424
Male10919
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Age 5-10 YearsAge 11-17 YearsTotal
Hispanic or Latino101
Not Hispanic or Latino192342
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Age 5-10 YearsAge 11-17 YearsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White192342
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Age 5-10 YearsAge 11-17 YearsTotal
Saudi Arabia31013
Italy527
Israel303
Tunisia516
Germany167
Spain347
Body mass index
Body mass index(kg/m2)Age 5-10 YearsAge 11-17 YearsTotal
Mean15.78 ± 3.33821.52 ± 4.84018.85 ± 5.071
08

Study locations

12 sites
  • Universtiats-Kinderlinik Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • University Hospital of Cologne
    Cologne, 50937, Germany
  • University Medical Center Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
  • U.O.C. Clinica Medica 1
    Padova, Padua 35128, Italy
  • Bambino Gesù Children's Hospital,
    Roma, 00165, Italy
  • King Abdullah International Medical Research Centre (KAIMRC),
    Riyadh, Saudi Arabia
  • King Faisal Specialist Hospital
    Riyadh, Saudi Arabia
  • Hospital Universitari Sant Joan
    Reus, Tarragona, 43204, Spain
  • Hospital Abente y Lago
    A Coruña, 15006, Spain
  • Hospital Clinico Universitario of Valencia
    Valencia, 46010, Spain
  • E.P.S. Fattouma Bourguiba Hospital
    Monastir, 5000, Tunisia
09

References and documents

Publications

  • Masana L, Zambon A, Schmitt CP, Taylan C, Driemeyer J, Cohen H, Buonuomo PS, Alashwal A, Al-Dubayee M, Kholaif N, Diaz-Diaz JL, Maatouk F, Martinez-Hervas S, Mangal B, Lowe S, Cunningham T. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study. Lancet Diabetes Endocrinol. 2024 Dec;12(12):880-889. doi: 10.1016/S2213-8587(24)00233-X. Epub 2024 Oct 16. PubMed 39426393 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Oct 2022, 22 months.

Results were first posted in Aug 2025, 2 years 10 months after primary completion.

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 23, 2020
StartActual
Dec 14, 2020
Primary completionActual
Oct 16, 2022
CompletionActual
Jun 6, 2024
Results first posted
Aug 27, 2025
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04681170
Lead sponsor
Amryt Pharma
Responsible party
Sponsor
First posted
Dec 23, 2020
Start date
Dec 14, 2020
Primary completion
Oct 16, 2022
Completion
Jun 6, 2024
Results posted
Aug 27, 2025
Last update
Aug 27, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS201038

Start the discussion